Related Experiment Video

Updated: Aug 11, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

Methicillin-Resistant S. aureus Ventilator-Associated Pneumonia: Strategies to Prevent and Treat

Anna P Lam1, Richard G Wunderink

  • 1Division of Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.

Seminars in Respiratory and Critical Care Medicine
|March 2, 2006
PubMed

Insights

Methicillin-resistant Staphylococcus aureus (MRSA) ventilator-associated pneumonia (VAP) is increasing. Current treatments like vancomycin show low success rates, necessitating research into new antibiotics for better outcomes.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Microbiology

Background:

  • Ventilator-associated pneumonias (VAPs) caused by methicillin-resistant Staphylococcus aureus (MRSA) are a growing concern in healthcare settings.
  • Risk factors for MRSA VAP include nasal carriage, prior antibiotic use, prolonged mechanical ventilation, and inadequate infection control.
  • MRSA's genetic elements confer resistance to multiple antibiotics, complicating treatment strategies.

Purpose of the Study:

  • To review the challenges in preventing and treating MRSA VAP.
  • To evaluate the efficacy of current antibiotic therapies for MRSA VAP.
  • To identify potential areas for future research and development of new treatments.

Main Methods:

  • Review of existing literature on MRSA VAP incidence, risk factors, and treatment outcomes.
  • Analysis of antibiotic efficacy, focusing on glycopeptides (e.g., vancomycin) and newer agents like linezolid.
  • Discussion of pharmacokinetic properties, such as lung penetration, influencing treatment success.

Main Results:

  • Vancomycin, the recommended initial therapy, demonstrates low success rates (35-57%) in MRSA VAP treatment.
  • Poor vancomycin penetration into lung tissue may contribute to treatment failures.
  • Linezolid shows higher cure and survival rates due to its favorable lung penetration.

Conclusions:

  • Current antibiotic options for MRSA VAP are limited, with suboptimal outcomes for standard therapies.
  • Optimizing dosing or exploring alternative antibiotics like linezolid is crucial for improving patient survival.
  • Further clinical investigation into novel antibiotics is essential for effective MRSA VAP management.

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Mechanical Ventilation II: Invasive Ventilation01:23

Mechanical Ventilation II: Invasive Ventilation

Ventilators are essential medical equipment used to aid patients with respiratory difficulties. Their primary function is to assist or replace spontaneous breathing by providing mechanical ventilation. There are two general classes of mechanical ventilators: negative-pressure and positive-pressure ventilators.
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...